Innovent Biologics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 1801.HK | ROIV | GMAB | 9969.HK | SMZ1.F | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | 154.42B | 27.61B | 33.89B | 21.56B | 11.09B | 37.99B |
| P/E (TTM) | 116.5 | — | 43.4 | 20.3 | 31.2 | 4.1 |
| Forward P/E | 34.9 | -27.5 | 34.9 | 53.2 | — | 11.2 |
| Price/book | 6.3 | 6.5 | 5.5 | 1.9 | 2.6 | 1.2 |
| Dividend yield | — | — | — | — | 2.90% | 1.69% |
| 1-year change | −3.41% | +85.85% | +91.12% | −16.21% | −23.60% | −51.32% |
| Today | +4.12% | +6.08% | −0.72% | +1.33% | +1.45% | +4.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 1801.HK news ›Innovent Biologics, Inc. Presents Phase 1 Study Data For IBI3001, A First-In-Class EGFR/B7H3 Bispecific ADC
Published on 10/25/2026 at 02:00 am EDT Of these, 78.9% had received =2 prior treatment. IBI3001 monotherapy demonstrated a manageable safety profile. During dose escalation, only one dose-limiting toxicity (DLT) event occurred in each of…
Innovent Biologics Through Its Subsidiary Altruist Biologics Constructs 2,000-Liter Single-Use Production Line in Hangzhou
Innovent Biologics announced Altruist Biologics' Hangzhou site was designed with a total antibody manufacturing capacity of 172,000 liters, with 80,000 liters currently operational across four... Innovent Biologics announced Altruist…
Alert on Innovent Biologics phase 3 study results withdrawn
An alert on Innovent Biologics announcing phase 3 study results of arcotatug tavatecan in gastric cancer has been withdrawn after the company clarified that the release should be disregarded. There... Alert on Innovent Biologics phase 3…
Hang Seng Index rebounds on Wednesday, Innovent Biologics, Anta Sports up nearly 10pc
Hong Kong stocks rebounded on Wednesday, tracking a broader recovery across global markets. The benchmark Hang Seng Index rose 141 points, or 0.6 percent, to 25,652 points at the close. The market turnover was HK$254.8 billion. Innovent…
Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Decrease in Short Interest
Posted by Tristan Rich on Oct 27th, 2026 Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 13,000 shares, a…
News from Innovent Biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Innovent Biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Oct 08, 2026, 20:00 ET…
Innovent Biologics announces approval of SYCUME in China for thyroid eye disease
The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug. Innovent Biologics announced the approval of SYCUME, a recombinant…
Innovent Biologics, Inc. Announces NMPA Acceptance Of A New Indication Application Of Sintilimab For The Treatment Of Advanced Melanoma
Published on 10/26/2026 at 05:18 am EDT By blocking the PD-1/programmed death-ligand 1 (PD-L1) pathway, which contributes to tumor immune tolerance, sintilimab reactivates the antitumor activity of lymphocytes to treat cancer. GC101 was…
Innovent Biologics, Inc.: Relative Strength Chart - Stock Hong Kong S.E.
Compare Innovent Biologics, Inc. with the company of your choice via a Relative Strength chart. Real-time 1801 price, Hong Kong S.E. stock exchange Relative Strength Chart Innovent Biologics, Inc. All financial news and data tailored to…
Innovent Biologics, Inc. Announces International Phase 3 Study of Arcotatug Tavatecan in Gastric Cancer Meets Dual Primary Endpoints of Pfs and Os
Published on 10/23/2026 at 07:38 am EDT The most common Grade =3 treatment-emergent adverse events (TEAEs) with arcotatug tavatecan versus TPC included anemia (20.4% vs. 13.1%), decreased neutrophil count (17.4% vs. 32.0%) and decreased…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com3
- themarketsdaily.com1
- thestandard.com.hk1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.